Q-omics provides the consensus-scored RPL27A profile across patient tissues and cancer cell-line models. RPL27A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL27A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPL27A protein abundance shows 24,340 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPL27A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL27A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL27A survival associations across molecular data types. RPL27A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL27A RNA expression–survival associations across cancer types. High RPL27A expression shows unfavorable associations in ACC, LIHC, KICH, KIRP and KIRC, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL27A RNA expression.
This table summarizes RPL27A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL27A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL27A shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, COAD, KIRP and CHOL. The KIRC box plot shows higher RPL27A RNA expression in tumor versus normal tissue (log2 FC = +0.965, t-test p < 0.001).
This table shows molecular features associated with RPL27A in patient tissues and cancer cell lines. In patient samples, RPL27A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL27A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
